{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T20:13:05Z","timestamp":1695845585556},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/rhu.0b013e3182288870","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T18:26:26Z","timestamp":1355941586000},"page":"269-271","source":"Crossref","is-referenced-by-count":8,"title":["Secondary Leprosy Infection in a Patient With Psoriasis During Treatment With Infliximab"],"prefix":"10.1097","volume":"17","author":[{"given":"Fabricia Martins","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana Mabel Ferreira","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarissa de Alencar Diogenes","family":"Rola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thereza L\u00facia","family":"Prata de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Telmo","family":"Valen\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparecida Tiemi","family":"Nagao-Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210207","first-page":"687","article-title":"Biological drugs targeting the immune response in the therapy of psoriasis.","volume":"2","author":"Pastore","year":"2008","journal-title":"Biologics"},{"key":"R2-8-20210207","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/TCRM.S3094","article-title":"Treatment of severe psoriasis with infliximab.","volume":"4","author":"Leman","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R3-8-20210207","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R5-8-20210207","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10067-009-1140-0","article-title":"Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation of a latent infection?","volume":"28","author":"Lopes","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R7-8-20210207","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R8-8-20210207","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R9-8-20210207","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1086\/505222","article-title":"Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases.","volume":"43","author":"Scollard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R10-8-20210207","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1590\/S1413-86702007000200009","article-title":"Salivary anti-PGL IgM and IgA titers and serum antibody IgG titers and avidities in leprosy patients and their correlation with time of infection and antigen exposure.","volume":"11","author":"Nagao-Dias","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"R11-8-20210207","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/keh685","article-title":"Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years.","volume":"44","author":"Lim","year":"2005","journal-title":"Rheumatology"},{"key":"R12-8-20210207","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"R13-8-20210207","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e3182288870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:56:06Z","timestamp":1620971766000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201108000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e3182288870","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}